로그인 회원가입
icon_bulk_order대량 주문 Acrobiosystems for English
0
장바구니가 비어 있습니다
A B C D E F G H I J K L M N O P Q R S T U V W X Y Z 0-9
Your Position: > Antibody > Rituximab > RIB-Y36

Anti-Rituximab Antibody (AY36) (recommended for ADA assay)

  • Source
    Anti-Rituximab Antibodies (recommended for ADA assay) antibody is produced from a hybridoma resulting from fusion of SP2/0 myeloma and B-lymphocytes obtained from a mouse immunized with Rituximab.
  • Isotype
    Mouse IgG1/kappa
  • Specificity
    Recognizes Rituximab specifically, no cross reactivity with other humanized antibodies.
  • Purity

    >95% as determined by SDS-PAGE.

  • Formulation

    Lyophilized from 0.22 μm filtered solution in Tris with Glycine, Arginine and NaCl, pH7.5 with trehalose as protectant.

    Contact us for customized product form or formulation.

  • Reconstitution

    Please see Certificate of Analysis for specific instructions.

    For best performance, we strongly recommend you to follow the reconstitution protocol provided in the CoA.

  • Storage

    For long term storage, the product should be stored at lyophilized state at -20°C or lower.

    Please avoid repeated freeze-thaw cycles.

    This product is stable after storage at:

    1. 4-8°C for 12 months in lyophilized state;
    2. -70°C for 12 months under sterile conditions after reconstitution.
SDS-PAGE
Rituximab SDS-PAGE

Anti-Rituximab Antibody (AY36) on SDS-PAGE under reducing (R) condition. The gel was stained with Coomassie Blue. The purity of the protein is greater than 95%.

Bioactivity-Elisa
 Rituximab ELISA

Anti-Rituximab Antibodies bridging ELISA for Anti-Drug Antibody (ADA) assay development.Immobilized rituximab at 1 µg/mL, add increasing concentrations of Anti-Rituximab Antibody (AY36) (Cat. No. RIB-Y36, 10% human serum) and then add biotinylated rituximab at 2 µg/mL. Detection was performed using HRP-conjugated streptavidin with a sensitivity of 9.7 ng/mL.

 Rituximab ELISA

Demonstration of the specificity of Anti-Rituximab Antibody (AY36) (Cat. No. RIB-Y36) to the rituximab.

Bioactivity-MSD
 Rituximab MSD

Anti-Rituximab Antibodies bridging MSD for Anti-Drug Antibody (ADA) assay development. Added the mix solution (biotinylated Rituximab at 5 µg/mL, SULFO-Rituximab at 5 µg/mL and increasing concentrations of Anti-Rituximab Antibody (AY36) (Cat. No. RIB-Y36, 100% human serum). Detection was performed using MSD Assay with a sensitivity of 0.97 ng/mL.

Bioactivity-SPR
 Rituximab SPR

Anti-Rituximab Antibody (AY36) (mouse IgG1, Cat. No. RIB-Y36) captured on CM5 chip via anti-mouse antibodies surface, can bind human rituximab with an affinity constant of 0.01 nM.

Bioactivity-FACS
 Rituximab FACS

FACS analysis shows that the binding of rituximab to 293F overexpressing CD20 was inhibited by increasing concentration of Anti-Rituximab Antibody (AY36) (Cat. No. RIB-Y36). The concentration of rituximab used is 10 ng/ml. The IC50 is 0.025 μg/ml (Routinely tested).

  • Background
    Rituxan is a genetically engineered chimeric murine/human monoclonal antibody directed against the CD20 antigen found on the surface of normal and malignant B lymphocytes. The antibody is an IgG1 kappa immunoglobulin containing murine light- and heavy-chain variable region sequences and human constant region sequences. Rituximab is composed of two heavy chains of 451 amino acids and two light chains of 213 amino acids
  • Clinical and Translational Updates

코멘트 (0)


재고상품 출발날짜: 영업일 기준 4일

가격(KRW) : 450,000

가격(KRW) : 3,270,000

보급 및 전시



Datasheet & Documentation

DMF 신청
DMF (Drug Master File)

관련 제품

신제품

문의와 컨텐츠

This web search service is supported by Google Inc.

totop